IL6R and rheumatoid arthritis: Tocilizumab, as an anti interleukin 6 receptor (IL-6R) monoclonal antibody, is launched in 2009 for the indication of RA, whose successful clinical use has proved the key role of IL-6 in RA pathogenesis (Choy et al., 2002).